Patents by Inventor Patrick Cornelis Nicolaas Rensen

Patrick Cornelis Nicolaas Rensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREVENTION, THERAPY AND PROGNOSIS/MONITORING IN SEPSIS AND SEPTIC SHOCK
    Publication number: 20160030516
    Abstract: The invention relates to the use of a peptide which binds to lipopolysaccharide (LPS) or lipoteichoic acid (LTA), for manufacturing a pharmaceutical composition for treating sepsis or septic shock, wherein the peptide comprises the amino acid sequence of apolipoprotein CI (apoCI) or a part thereof that comprises at least the amino acids of the C-terminal helix of apoCI. The use of human apoCI is preferred. The peptide can be administered clinically to patients who have sepsis or threaten to develop sepsis. Measurement of the apoCI content in blood can be utilized for determining the severity and prognosis of the course of the septic condition or for monitoring an anti-sepsis treatment.
    Type: Application
    Filed: October 21, 2015
    Publication date: February 4, 2016
    Applicant: NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO
    Inventors: PATRICK CORNELIS NICOLAAS RENSEN, ALOYSIUS MARIA HAVEKES
  • Prevention therapy and prognosis/monitoring in sepsis and septic shock
    Patent number: 9176153
    Abstract: The invention relates to the use of a peptide which binds to lipopolysaccharide (LPS) or lipoteichoic acid (LTA), for manufacturing a pharmaceutical composition for treating sepsis or septic shock, wherein the peptide comprises the amino acid sequence of apolipoprotein CI (apoCI) or a part thereof that comprises at least the amino acids of the C-terminal helix of apoCI. The use of human apoCI is preferred. The peptide can be administered clinically to patients who have sepsis or threaten to develop sepsis. Measurement of the apoCI content in blood can be utilized for determining the severity and prognosis of the course of the septic condition or for monitoring an anti-sepsis treatment.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: November 3, 2015
    Assignee: NEDERLANDSE ORGANISATIE VOOR TOEGEPASTNATUURWETENSCHAPPELIJK ONDERZOEK TNO
    Inventors: Patrick Cornelis Nicolaas Rensen, Aloysius Maria Havekes